Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

28 evidence topics · 16 sources

Registered trials of investigational disease-modifying therapies: mechanism, comparator, and design
TrialInterventionMechanism of actionPopulationComparisonStudy designEstimated enrolment
INVEST-HD (NCT07326709)“Votoplam”View highlighted excerpt for this quote“Small molecule splicing modulator”View highlighted excerpt for this quote“Early HD (CAG ≥40, UHDRS TFC=13, TMS 7-25, IS ≥90”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, parallel-group (phase III)”View highlighted excerpt for this quote“770”View highlighted excerpt for this quote
FALCON-HD (NCT07378644)“SKY-0515”View highlighted excerpt for this quote“mRNA splicing modulator designed to lower mHTT and PMS1”View highlighted excerpt for this quote“Early HD; UHDRS TFC ≥10, TMS ≥6, IS ≥70”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, dose-ranging, parallel-group (phase II/III)”View highlighted excerpt for this quote“400”View highlighted excerpt for this quote
NCT06826612“Intraparenchymal infusion of SPK-10001 into caudate and putamen bilaterally”View highlighted excerpt for this quote“AAV-mediated gene therapy delivering therapeutic construct to striatum to modify disease progression”View highlighted excerpt for this quote“HD-ISS stage 1 or 2 HD; UHDRS TFC ≥11”View highlighted excerpt for this quote“Placebo/sham surgery”View highlighted excerpt for this quote“Randomized, sequential dose-escalation, quadruple-masked, parallel assignment”View highlighted excerpt for this quote“53”View highlighted excerpt for this quote
NCT06585449“ALN-HTT02”View highlighted excerpt for this quote“RNA interference selectively targeting exon 1 of HTT mRNA”View highlighted excerpt for this quote“HD-ISS stage 2 or early stage 3 HD”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, parallel assignment, single dose”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote
POINT-HD (NCT07246941)“RG6496”View highlighted excerpt for this quote“Intrathecally administered HTT-lowering therapy; SNP-targeted approach”View highlighted excerpt for this quote“HD gene-expansion carrierss with target SNP, CAG >39, UHDRS TFC ≥10, TMS ≥6, IS ≥70”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, placebo-controlled, single-ascending-dose study with open-label extension (phase I)”View highlighted excerpt for this quote“40”View highlighted excerpt for this quote
VO659-CT01 (NCT05822908)“Intrathecal administration of VO659”View highlighted excerpt for this quote“ASO targeting mutant HTT and ataxin RNA to reduce toxic protein levels”View highlighted excerpt for this quote“SCA1, SCA3, HD”View highlighted excerpt for this quote“None”View highlighted excerpt for this quote“Open-label, non-randomized”View highlighted excerpt for this quote“68”View highlighted excerpt for this quote
NCT07344519“ER2001”View highlighted excerpt for this quote“Small interfering RNA”View highlighted excerpt for this quote“Adults with early manifest HD who completed study ER2001-001”View highlighted excerpt for this quote“None”View highlighted excerpt for this quote“Open-label, dose-escalation, single-group (phase I)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote
GENERATION HD2 (NCT05686551)“Tominersen”View highlighted excerpt for this quote“Non-allele-selective ASO”View highlighted excerpt for this quote“Prodromal and early HD”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, dose-finding trial”View highlighted excerpt for this quote“360”View highlighted excerpt for this quote
SELECT-HD (NCT05032196)“WVE-003”View highlighted excerpt for this quote“Allele-selective ASO”View highlighted excerpt for this quote“Early HD”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial”View highlighted excerpt for this quote“36”View highlighted excerpt for this quote
PRECISE-HD (NCT07609108)“Pridopidine”View highlighted excerpt for this quote“Sigma-1 receptor activation”View highlighted excerpt for this quote“Manifest HD (not receiving antidopaminergic medications for ≥6 months before screening)”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, parallel-group trial with 52-week treatment period followed by a 2-year open-label extension (phase III)”View highlighted excerpt for this quote“400”View highlighted excerpt for this quote
Tominersen: GENERATION HD1 biomarkers, adverse events, and post hoc subgroup analyses

“The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The absence of whole-brain volume loss in the context of ventricular expansion and the absence of a correlation between the change in CSF NfL levels and change in ventricular volume suggest that increases in ventricular volume do not reflect increased atrophy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A transient increase was seen in CSF NfL levels in the every-8-week tominersen group at week 21; although neuroaxonal damage may be implicated, increased levels of leukocytes and total protein in CSF in some participants suggest an inflammatory component” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results of post hoc analyses support the hypothesis that younger participants (who have less disease burden) may benefit from tominersen therapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“this hypothesis is currently being tested in a phase 2 dose-finding trial (GENERATION HD2; NCT05686551).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Direct head-to-head comparison of ifezuntirgene inilparvovec with an approved or investigational therapy

No evidence found.